Dalhousie Myeloma Research Group

Our Mission

To channel the skills of a uniquely diverse group of experts to offer world class advancement in multiple myeloma research through translational science and integrated approaches.

Team Members

Objectives

• Establish & maintain a viable Myeloma Tumour Bank & Database (MTBD)
• Establish a genetic panel to assess Multiple Myeloma (MM) prognosis
• Investigate genetic and environmental aspects that may explain familial clustering of MM within Nova Scotia
• Identify epigenetic signatures that define high risk of disease progression
• Understand how genetic mutations in MM can predict interactions with the immune system to guide therapy
• Develop NK cell-based immunotherapy for precision medicine against MM
• Improve access to cutting-edge research for Atlantic Canadians to improve treatment options and efficacy

Methods & Technologies

Tumour genomics (Illumina) - epigenetics (Illumina; ChIP-Seq) - transcriptomics (Illumina, qPCR) - Immunogenomics (PCR, sequencing, SSO) - Immunology (model systems: flow cytometry, in vitro stimulations, humanized mice, human lymphocytes, CRISPR-Cas9), mass-spectrometry-based proteomics, and immune-metabolomics, in vivo animal modelling and preclinical testing, MHC ligandomics and high throughput tumour epitope discovery

Funding Sources

Effective

Partners